Thankfully, glutathione strengthens the gut wall, allowing for a healthier digestive system
Appropriate dose adjustments and frequent clinical monitoring are necessary for such patients
CLINICAL TRIAL EVIDENCE FOR DUAL GLP-1/GLUCAGON RAs AND TRIPLE AGONISTS IN MASH Survodutide Survodutide, a weekly dual GLP-1/GCG agonist, was assessed in a phase 2 dose-finding trial (NCT04771273) including 293 individuals with histologically confirmed MASH and fibrosis stages F1-F3 [46]
The integration of GLP-1 receptor agonists, such as semaglutide and liraglutide, into our practice aligns with our mission to provide effective, medically supervised weight loss options that complement our surgical and non-surgical aesthetic offerings
Although some studies have demonstrated benefits such as increased lean body mass and improved body composition (in populations with clinical need for the drugs), these gains have not consistently translated into enhancements in muscle strength, physical performance, or overall quality of life